AbbVie Inc.
Public company- Headquarters
- NORTH CHICAGO, Illinois
- Ticker
- ABBV
- CIK
- 0001551152
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
| Notice date | Workers affected | Cumulative |
|---|---|---|
| Nov 10, 2025 | 9 | 9 |
| Nov 10, 2025 | 48 | 57 |
| Nov 10, 2025 | 2 | 59 |
| May 19, 2026 | 85 | 144 |
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorJennifer L. Davis | Nov 2, 2026 | Departed |
| CEOJennifer L. Davis | Nov 2, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ABBOTT LABORATORIES
Plant closure: CA
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- JOHNSON & JOHNSON
WARN notice: New Brunswick, NJ
- Merck & Co., Inc.
WARN notice: Rahway, NJ
- Executive departure
Class II director departs: Jennifer L. Davis
Jennifer L. Davis, Class II director of AbbVie Inc., resigns the role, effective November 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 2, 2026Role: Class II director
- Executive appointment
CEO appointed: Jennifer L. Davis
Jennifer L. Davis was named Chief Executive Officer of AbbVie Inc.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 2, 2026Role: Chief Executive Officer
- Executive appointment
Class II director appointed: John M. Carethers
John M. Carethers was named Class II director of AbbVie Inc., effective October 14, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 15, 2026Role: Class II director
Last verified Nov 8, 2026